



ORAL PRESENTATION

Open Access

# rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses

P Bart<sup>1\*</sup>, Y Huang<sup>2</sup>, N Frahm<sup>3</sup>, S Karuna<sup>3</sup>, M Allen<sup>4</sup>, NK Kochar<sup>3</sup>, S Chappuis<sup>1</sup>, J Gaillard<sup>1</sup>, B Graham<sup>5</sup>, G Pantaleo<sup>1</sup>

From AIDS Vaccine 2012

Boston, MA, USA. 9-12 September 2012

## Background

HVTN 078 is a randomized, double blind phase 1b clinical trial to evaluate the safety and immunogenicity of heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adult participants.

## Methods

The rAd5 vaccine expressed clade B Gag-Pol and the gp140 of HIV-1 92RW020 (clade A), HxB2/Bal-V3/ $\Delta$ V1V2 (clade B) and 97ZA012 (clade C). The NYVAC-B vaccine expressed clade B Gag-Pol-Nef and the gp120 of Bx08 (clade B). 80 healthy, HIV-1 uninfected, Ad5 seronegative volunteers, aged 18 to 45 years, were randomized to the placebo arm (n=5) or one of 4 treatment (T) arms: T1 (n=30), 2xNYVAC-B/1xrAd5 (10E10); T2 (n=15), 1xrAd5 (10E8)/2xNYVAC-B; T3 (n=15), 1xrAd5 (10E9)/2xNYVAC-B; T4 (n=15), 1xrAd5 (10E10)/2xNYVAC-B.

Intracellular cytokine staining responses (percent of CD4+ and CD8+ T cells producing IFN- $\gamma$  and/or IL-2 in response to stimulation with global PTE peptides) were assessed two weeks after the final vaccination.

## Results

For CD4+ T cells, the overall response rates for IFN- $\gamma$  and/or IL-2 among the vaccinees were 42.9%, 93.3%, 92.3%, and 85.7% for T1-T4, respectively; and the median response magnitudes for positive responders were 0.26%, 0.76%, 0.40%, and 0.76% for T1- T4, respectively. Both response rates ( $p < 0.01$ ) and magnitudes ( $p < 0.03$ ) of CD4+

T-cell responses were significantly lower in T1 compared to the other three treatment groups. For CD8+ T cells, the overall response rates were 65.5%, 73.3%, 76.9% and 85.7% for T1-T4, respectively; and median response magnitudes for positive responders were 0.32%, 0.99%, 1.86%, and 1.65%, respectively. Response rates were not significantly different between groups; however, response magnitudes were significantly lower in T1 compared to the other three arms ( $p < 0.04$ ).

## Conclusion

Priming with rAd5 followed by NYVAC-B boost is superior to priming with NYVAC-B followed by rAd5 boost for both response rates and the magnitude of CD4+ and CD8+ T-cell responses.

## Author details

<sup>1</sup>CHUV, Lausanne, Switzerland. <sup>2</sup>SCHARP, Seattle, WA, USA. <sup>3</sup>HVTN, Seattle, WA, USA. <sup>4</sup>DAIDS, NIAID, NIH, Bethesda, MD, USA. <sup>5</sup>Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-O72

**Cite this article as:** Bart *et al.*: rAd5 prime/NYVAC-B boost regimen is superior to NYVAC-B prime/rAd5 boost regimen for both response rates and magnitude of CD4 and CD8 T-cell responses. *Retrovirology* 2012 **9** (Suppl 2):O72.

<sup>1</sup>CHUV, Lausanne, Switzerland

Full list of author information is available at the end of the article